Cargando…
Impact of short-term discontinuation of ivermectin-based chemoprevention on onchocerciasis transmission in endemic settings with long history of mass drug administration
BACKGROUND: The control of onchocerciasis currently relies on annual distribution of single dose ivermectin. Because ivermectin has minimal effects on the adult parasite, mass drug administration (MDA) campaigns against onchocerciasis require at least 15 years of annual uninterrupted ivermectin dist...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132555/ https://www.ncbi.nlm.nih.gov/pubmed/37058547 http://dx.doi.org/10.1371/journal.pntd.0011250 |
_version_ | 1785031406571749376 |
---|---|
author | Efon-Ekangouo, Arnauld Nana-Djeunga, Hugues C. Nzune-Toche, Narcisse Dongmo-Yemele, Raïssa Bopda, Jean Ongbassomben, Viviane Sumo, Laurentine Geiger, Anne Nutman, Thomas B. Kamgno, Joseph |
author_facet | Efon-Ekangouo, Arnauld Nana-Djeunga, Hugues C. Nzune-Toche, Narcisse Dongmo-Yemele, Raïssa Bopda, Jean Ongbassomben, Viviane Sumo, Laurentine Geiger, Anne Nutman, Thomas B. Kamgno, Joseph |
author_sort | Efon-Ekangouo, Arnauld |
collection | PubMed |
description | BACKGROUND: The control of onchocerciasis currently relies on annual distribution of single dose ivermectin. Because ivermectin has minimal effects on the adult parasite, mass drug administration (MDA) campaigns against onchocerciasis require at least 15 years of annual uninterrupted ivermectin distribution. Mathematical models have predicted that short-term disruption of MDA (as was seen during COVID-19) could impacted the microfilaridermia prevalence depending on the pre-control endemicity and the histories of treatment, requiring corrective measures (such as biannual MDA) to mitigate the effect on onchocerciasis elimination. Field evidence supporting this prediction, however, has yet to be gathered. This study aimed to assess the impact of ~2 years disruption of MDA on onchocerciasis transmission indicators. METHODOLOGY: A cross-sectional survey was carried out in 2021 in seven villages of Bafia and Ndikinimeki, two health districts located in the Centre Region, Cameroon, where MDA has been ongoing for two decades, but interrupted in 2020 as a response to the COVID-19 pandemic. Volunteers aged 5 years and above were enrolled for clinical and parasitological examinations for onchocerciasis. Data were compared with pre-COVID-19 prevalence and intensity of infection from the same communities to measure changes over time. PRINCIPAL FINDINGS: A total of 504 volunteers (50.3% males), aged 5–99 years (Median: 38; IQR: 15–54) was enrolled in the two health districts. The overall prevalence of microfilaridermia in 2021 was similar in Ndikinimeki health district (12.4%; 95% CI: 9.7–15.6) and Bafia health district (15.1%; 95% CI: 11.1–19.8) (p-value = 0.16). Microfilaridermia prevalences were either similar between 2018 and 2021 in the communities of Ndikinimeki health district (19.3% vs 12.8% (p = 0.057) for Kiboum 1; and 23.7% vs 21.4% (p = 0.814) for Kiboum 2), or higher in 2019 compared to 2021 in the communities of Bafia health district (33.3% vs 20.0% (p = 0.035) for Biatsota). The mean microfilarial densities in these communities dropped from 5.89 (95% CI: 4.77–7.28) mf/ss to 2.4 (95% CI: 1.68–3.45) mf/ss (p-value < 0.0001), and from 4.81 (95% CI: 2.77–8.31) mf/ss to 4.13 (95% CI: 2.49–6.86) mf/ss (p-value < 0.02) in Bafia and Ndikinimeki health districts, respectively. Community Microfilarial Load (CMFL) dropped from 1.08–1.33 mf/ss in 2019 to 0.052–0.288 mf/ss in 2021 in Bafia health district while remaining stable in the Ndikinimeki health district. CONCLUSION/SIGNIFICANCE: The continued decline in prevalence and CMFL observed ~2 years after MDA disruption is consistent with mathematical predictions (ONCHOSIM) and shows that additional efforts and resources are not needed to mitigate the effects of short-term MDA disruption in highly endemic settings prior to intervention with long treatment histories. |
format | Online Article Text |
id | pubmed-10132555 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-101325552023-04-27 Impact of short-term discontinuation of ivermectin-based chemoprevention on onchocerciasis transmission in endemic settings with long history of mass drug administration Efon-Ekangouo, Arnauld Nana-Djeunga, Hugues C. Nzune-Toche, Narcisse Dongmo-Yemele, Raïssa Bopda, Jean Ongbassomben, Viviane Sumo, Laurentine Geiger, Anne Nutman, Thomas B. Kamgno, Joseph PLoS Negl Trop Dis Research Article BACKGROUND: The control of onchocerciasis currently relies on annual distribution of single dose ivermectin. Because ivermectin has minimal effects on the adult parasite, mass drug administration (MDA) campaigns against onchocerciasis require at least 15 years of annual uninterrupted ivermectin distribution. Mathematical models have predicted that short-term disruption of MDA (as was seen during COVID-19) could impacted the microfilaridermia prevalence depending on the pre-control endemicity and the histories of treatment, requiring corrective measures (such as biannual MDA) to mitigate the effect on onchocerciasis elimination. Field evidence supporting this prediction, however, has yet to be gathered. This study aimed to assess the impact of ~2 years disruption of MDA on onchocerciasis transmission indicators. METHODOLOGY: A cross-sectional survey was carried out in 2021 in seven villages of Bafia and Ndikinimeki, two health districts located in the Centre Region, Cameroon, where MDA has been ongoing for two decades, but interrupted in 2020 as a response to the COVID-19 pandemic. Volunteers aged 5 years and above were enrolled for clinical and parasitological examinations for onchocerciasis. Data were compared with pre-COVID-19 prevalence and intensity of infection from the same communities to measure changes over time. PRINCIPAL FINDINGS: A total of 504 volunteers (50.3% males), aged 5–99 years (Median: 38; IQR: 15–54) was enrolled in the two health districts. The overall prevalence of microfilaridermia in 2021 was similar in Ndikinimeki health district (12.4%; 95% CI: 9.7–15.6) and Bafia health district (15.1%; 95% CI: 11.1–19.8) (p-value = 0.16). Microfilaridermia prevalences were either similar between 2018 and 2021 in the communities of Ndikinimeki health district (19.3% vs 12.8% (p = 0.057) for Kiboum 1; and 23.7% vs 21.4% (p = 0.814) for Kiboum 2), or higher in 2019 compared to 2021 in the communities of Bafia health district (33.3% vs 20.0% (p = 0.035) for Biatsota). The mean microfilarial densities in these communities dropped from 5.89 (95% CI: 4.77–7.28) mf/ss to 2.4 (95% CI: 1.68–3.45) mf/ss (p-value < 0.0001), and from 4.81 (95% CI: 2.77–8.31) mf/ss to 4.13 (95% CI: 2.49–6.86) mf/ss (p-value < 0.02) in Bafia and Ndikinimeki health districts, respectively. Community Microfilarial Load (CMFL) dropped from 1.08–1.33 mf/ss in 2019 to 0.052–0.288 mf/ss in 2021 in Bafia health district while remaining stable in the Ndikinimeki health district. CONCLUSION/SIGNIFICANCE: The continued decline in prevalence and CMFL observed ~2 years after MDA disruption is consistent with mathematical predictions (ONCHOSIM) and shows that additional efforts and resources are not needed to mitigate the effects of short-term MDA disruption in highly endemic settings prior to intervention with long treatment histories. Public Library of Science 2023-04-14 /pmc/articles/PMC10132555/ /pubmed/37058547 http://dx.doi.org/10.1371/journal.pntd.0011250 Text en https://creativecommons.org/publicdomain/zero/1.0/This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication. |
spellingShingle | Research Article Efon-Ekangouo, Arnauld Nana-Djeunga, Hugues C. Nzune-Toche, Narcisse Dongmo-Yemele, Raïssa Bopda, Jean Ongbassomben, Viviane Sumo, Laurentine Geiger, Anne Nutman, Thomas B. Kamgno, Joseph Impact of short-term discontinuation of ivermectin-based chemoprevention on onchocerciasis transmission in endemic settings with long history of mass drug administration |
title | Impact of short-term discontinuation of ivermectin-based chemoprevention on onchocerciasis transmission in endemic settings with long history of mass drug administration |
title_full | Impact of short-term discontinuation of ivermectin-based chemoprevention on onchocerciasis transmission in endemic settings with long history of mass drug administration |
title_fullStr | Impact of short-term discontinuation of ivermectin-based chemoprevention on onchocerciasis transmission in endemic settings with long history of mass drug administration |
title_full_unstemmed | Impact of short-term discontinuation of ivermectin-based chemoprevention on onchocerciasis transmission in endemic settings with long history of mass drug administration |
title_short | Impact of short-term discontinuation of ivermectin-based chemoprevention on onchocerciasis transmission in endemic settings with long history of mass drug administration |
title_sort | impact of short-term discontinuation of ivermectin-based chemoprevention on onchocerciasis transmission in endemic settings with long history of mass drug administration |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132555/ https://www.ncbi.nlm.nih.gov/pubmed/37058547 http://dx.doi.org/10.1371/journal.pntd.0011250 |
work_keys_str_mv | AT efonekangouoarnauld impactofshorttermdiscontinuationofivermectinbasedchemopreventionononchocerciasistransmissioninendemicsettingswithlonghistoryofmassdrugadministration AT nanadjeungahuguesc impactofshorttermdiscontinuationofivermectinbasedchemopreventionononchocerciasistransmissioninendemicsettingswithlonghistoryofmassdrugadministration AT nzunetochenarcisse impactofshorttermdiscontinuationofivermectinbasedchemopreventionononchocerciasistransmissioninendemicsettingswithlonghistoryofmassdrugadministration AT dongmoyemeleraissa impactofshorttermdiscontinuationofivermectinbasedchemopreventionononchocerciasistransmissioninendemicsettingswithlonghistoryofmassdrugadministration AT bopdajean impactofshorttermdiscontinuationofivermectinbasedchemopreventionononchocerciasistransmissioninendemicsettingswithlonghistoryofmassdrugadministration AT ongbassombenviviane impactofshorttermdiscontinuationofivermectinbasedchemopreventionononchocerciasistransmissioninendemicsettingswithlonghistoryofmassdrugadministration AT sumolaurentine impactofshorttermdiscontinuationofivermectinbasedchemopreventionononchocerciasistransmissioninendemicsettingswithlonghistoryofmassdrugadministration AT geigeranne impactofshorttermdiscontinuationofivermectinbasedchemopreventionononchocerciasistransmissioninendemicsettingswithlonghistoryofmassdrugadministration AT nutmanthomasb impactofshorttermdiscontinuationofivermectinbasedchemopreventionononchocerciasistransmissioninendemicsettingswithlonghistoryofmassdrugadministration AT kamgnojoseph impactofshorttermdiscontinuationofivermectinbasedchemopreventionononchocerciasistransmissioninendemicsettingswithlonghistoryofmassdrugadministration |